Phosphoproteomic subtyping of gastric cancer reveals dynamic transformation with chemotherapy and guides targeted cancer treatment

Cell Rep. 2024 Oct 22;43(10):114774. doi: 10.1016/j.celrep.2024.114774. Epub 2024 Oct 1.

Abstract

There are only a few effective molecular targeted agents for advanced unresectable or recurrent advanced gastric cancer (AGC), which has a poor prognosis with a median survival time of less than 14 months. Focusing on phosphorylation signaling in cancer cells, we have been developing deep phosphoproteome analysis from minute endoscopic biopsy specimens frozen within 20 s of collection. Phosphoproteomic analysis of 127 fresh-frozen endoscopic biopsy samples from untreated patients with AGC revealed three subtypes reflecting different cellular signaling statuses. Subsequent serial biopsy analysis has revealed the dynamic mesenchymal transitions within cancer cells, along with the concomitant rewiring of the kinome network, ultimately resulting in the conversion to the epithelial-mesenchymal transition (EMT) subtype throughout treatment. We present our investigation of intracellular signaling related to the EMT in gastric cancer and propose therapeutic approaches targeting AXL. This study also provides a wealth of resources for the future development of treatments and biomarkers for AGC.

Keywords: AXL; CP: Cancer; EMT; endoscopic biopsy; gastric cancer; gilteritinib; phosphorylation signal; proteome; serial biopsy analysis.

MeSH terms

  • Axl Receptor Tyrosine Kinase
  • Cell Line, Tumor
  • Epithelial-Mesenchymal Transition*
  • Female
  • Humans
  • Male
  • Molecular Targeted Therapy
  • Phosphoproteins* / metabolism
  • Phosphorylation
  • Proteomics* / methods
  • Receptor Protein-Tyrosine Kinases / metabolism
  • Signal Transduction
  • Stomach Neoplasms* / drug therapy
  • Stomach Neoplasms* / metabolism
  • Stomach Neoplasms* / pathology

Substances

  • Phosphoproteins
  • Receptor Protein-Tyrosine Kinases
  • Axl Receptor Tyrosine Kinase